Review of Operations Directors’ Report Chairman’s Letter CEO’s Report Financial Report Shareholder Information 5 Annual Report 2025 Research and Development › EXO-OC™ Ovarian Cancer screening test achieved 77% sensitivity at >99.6% specificity for detecting ovarian cancer across all stages, and 100% sensitivity for early-stage I and II disease › EXO-OC data presented at ASCO 2025 and provisional patent application filed on 29 May 2025 to secure intellectual property rights protecting the biomarkers and combinations › CAR-NK-exosomes achieved 88% cell death in triple negative breast cancer and non-small cell lung cancer cells in vitro › Peter Mac engaged to further validate CAR-exosomes in Triple Negative Breast Cancer (TNBC) in vitro and in vivo studies › NeuCA15-3™ Breast Cancer monitoring test completes disease specificity testing and test being transferred to bead-based assay for commercialisation › Neu-CA15-3 diagnostic performance published in international peer reviewed journal Breast Cancer Research and Treatment › Capital raise of $9.4m completed in July 2024 › Cash of $6.5 million at 30 June 2025 to fund operations, pipeline development and commercial initiatives › Net loss of $6.9 million for the year ended 30 June 2025 › Research and Development Tax Refund of $1.27m recognised for the 2025 financial year › Mary Harney appointed Non-Executive Director, bringing deep understanding of applied life science research and experience in biopharmaceutical regulatory affairs and commercialisation › Dr Emma Ball appointed Chief Commercial Officer (CCO), bringing extensive business development and licensing experience in therapeutics and life sciences › Medical and Scientific Advisory Board established to provide expert guidance on INOVIQ’s diagnostic and therapeutic programs Financial Corporate
RkJQdWJsaXNoZXIy MjE2NDg3